Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
RESEARCH TOOLSreports
Holding FDMT?
Track your performance easily
FDMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.58 - $36.25
Previous Close$6.31
Volume4.77M
Average Volume (3M)952.64K
Market Cap
$267.20M
Enterprise Value-$209.86M
Total Cash (Recent Filing)$501.89M
Total Debt (Recent Filing)$24.83M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Mar 31, 2025EPS Estimate
-$0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding46,227,709
10 Day Avg. Volume1,160,085
30 Day Avg. Volume952,641
Standard Deviation0.33
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.53
Price to Sales (P/S)15717.42
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-11.66K
Enterprise Value/Gross Profit-10.13
Enterprise Value/Ebitda1.48
Forecast
1Y Price Target
$34.80Price Target Upside451.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
4D Molecular Therapeutics News
PremiumCompany Announcements
4D Molecular Therapeutics’ Positive Q3 and Strategic Advances
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's cash position is expected to provide financial stability into the first half of 2027.
Gene Therapy Durability4D-150's potential for multiyear durability is highly differentiated compared to current standard treatments, justifying a large commercial opportunity.
Regulatory SupportThe trial design is based on alignment with the FDA, indicating regulatory support for the program.
Bears Say
Commercial ChallengesThe real world setting could pose non-clinical obstacles in the event of a potential commercial launch and thereby hamper the commercial opportunity for wAMD gene therapies.
Investor SentimentInvestors appear to have mixed views on the data announcement and path forward.
Market CompetitionThe potential for other long-acting options to enter this market sooner than expected and the expected entry of biosimilars are reasons to be conservative in estimates.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $5.58 and its highest was $36.25 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
Currently, no data Available
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Mar 31, 2025 which is in 99 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.676 by -$0.114.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -$0.84.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 46,227,710 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.676. Following the earnings report the stock price went up 4.021%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Among the largest hedge funds holding 4D Molecular Therapeutics’s share is RA Capital Management. It holds 4D Molecular Therapeutics’s shares valued at 55M.
---
4D Molecular Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.80 (451.51% Upside)
$34.80 (451.51% Upside)
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
67.04%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.
---
FDMT Stock 12 Month Forecast
Average Price Target
$34.80
▲(451.51% Upside)
Technical Analysis
Adverum Biotechnologies
―
Krystal Biotech
―
Rocket Pharmaceuticals
―
Crispr Therapeutics AG
―
Best Analysts Covering FDMT
1 Year
1 Year Success Rate
5/16 ratings generated profit
1 Year Average Return
-20.10%
reiterated a buy rating last month
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of -20.10% per trade.
---